Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5758-5763

  Vu, D H ^a,b,c   Bolhuis, M S ^b   Koster, R A ^b   Greijdanus, B ^b   De Lange, W C M ^b   Van Altena, R ^b   Brouwers, J R B J ^a   Uges, D R A ^b   Alffenaar, J W C ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c HANOI UNIVERSITY OF PHARMACY   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CLOFAZIMINE; COTRIMOXAZOLE; ERTAPENEM; ETHAMBUTOL; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE;

ACCURACY; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; DRUG EXPOSURE; DRUG MONITORING; FEMALE; HUMAN; LIMIT OF QUANTITATION; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PLASMA; PRIORITY JOURNAL; REGRESSION ANALYSIS; REPRODUCIBILITY; VALIDATION STUDY;

ACETAMIDES; ADULT; ANTITUBERCULAR AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRIED BLOOD SPOT TESTING; DRUG MONITORING; FEMALE; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84868030937     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01054-12     Document Type: Article

References (34)

1. Alffenaar JW, et al. 2010. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther. Drug Monit. 32:97-101.
2. Alffenaar JW, et al. 2010. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin. Pharmacokinet. 49:559-565.
3. Antony SJ, Harrell V, Christie JD, Adams HG, Rumley RL. 1995. Clinical differences between pulmonary and extrapulmonary tuberculosis: a 5-year retrospective study. J. Natl. Med. Assoc. 87:187-192.
4. Bland JM, Altman DG. 1999. Measuring agreement in method comparison studies. Stat. Methods Med. Res. 8:135-160.
5. Bolhuis MS, Pranger AD, Alffenaar JW. 2012. Linezolid: safety and efficacy monitoring. Eur. Respir. J. 39:1275-1276. (Letter.)
6. Bolhuis MS, et al. 2010. Clarithromycin significantly increases linezolid serum concentrations. Antimicrob. Agents Chemother. 54:5418-5419.
7. Conte JE, Jr, Golden JA, Kipps J, Zurlinden E. 2002. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. 46:1475-1480.
8. Cox H, Ford N. 2012. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 16:447-454.
9. Cynamon MH, Klemens SP, Sharpe CA, Chase S. 1999. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 43:1189-1191.
10. Dooley KE, et al. 17 July 2012, posting date. World Health Organization group V drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J. Infect. Dis. doi:10.1093/infdis/jis460.
11. Dryden MS. 2011. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J. Antimicrob. Chemother. 66(Suppl 4):iv7-iv15.
12. Edelbroek PM, van der Heijden J, Stolk LM. 2009. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther. Drug Monit. 31:327-336.
13. Emmons G, Rowland M. 2010. Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis 2:1791-1796.
14. Fortun J, et al. 2005. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56:180-185.
15. Gebhart BC, Barker BC, Markewitz BA. 2007. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 27:476-479.
16. Harmelink IM, Alffenaar JW, Wessels AM, Greijdanus B, Uges DR. 2008. A rapid and simple liquid chromatography-tandem mass spectrom-etry method for the determination of linezolid in human serum. EJHP Science 14:3-7.
17. Koh WJ, et al. 30 May 2012. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J. Antimicrob. Chemother. 67:2056-2057. [Epub ahead of print.] doi:10.1093/jac/dks078.
18. Li W, Tse FL. 2010. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 24:49-65.
19. McGee B, et al. 2009. Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 53:3981-3984.
20. Pea F, et al. 2010. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob. Agents Chemother. 54:4605-4610.
21. Prammananan T, Chaiprasert A, Leechawengwongs M. 2009. In vitro activity of linezolid against multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR)-TB isolates. Int. J. Antimicrob. Agents. 33:190-191.
22. Sasaki T, et al. 2011. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob. Agents Chemother. 55:1867-1873.
23. Singla R, et al. 2012. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur. Respir. J. 39:956-962.
24. Spooner N, Lad R, Barfield M. 2009. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal. Chem. 81:1557-1563.
25. Spooner N, Ramakrishnan Y, Barfield M, Dewit O, Miller S. 2010. Use of DBS sample collection to determine circulating drug concentrations in clinical trials: practicalities and considerations. Bioanalysis 2:1515-1522.
26. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. 2011. Multi-drug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J. Infect. Dis. 204:1951-1959.
27. U.S. Department of Health and Human Services, Food and Drug Administration. 2001. Guidance for industry. Bioanalytical method validation. U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
28. van Klingeren B, Dessens-Kroon M, van der Laan T, Kremer K, van Soolingen D. 2007. Drug susceptibility testing of Mycobacterium tuberculosis complexbyuse ofa high-throughput, reproducible, absolute concentration method. J. Clin. Microbiol. 45:2662-2668.
29. Vinh DC, Rubinstein E. 2009. Linezolid: a review of safety and tolerability. J. Infect. 59(Suppl 1):S59 -S74.
30. Vu DH, Alffenaar JW, Edelbroek PM, Brouwers JR, Uges DR. 2011. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr. Pharm. Des. 17:2931-2939.
31. Vu DH, Koster RA, Alffenaar JW, Brouwers JR, Uges DR. 2011. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 879:1063-1070.
32. Williams KN, et al. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53:1314-1319.
33. World Health Organization. 2010. Treatment of tuberculosis: guidelines, 4th ed. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who. int/publications/2010/9789241547833-eng.pdf.
34. Yew WW, Chau CH, Wen KH. 2008. Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 12: 345-346.